IMMUNOTECH BIOPHARM LTD |
Market Closed -
Other stock markets
|
5-day change | 1st Jan Change | ||
| 3.3 HKD | +5.10% |
|
-3.79% | -34.00% |
| Mar. 29 | Immunotech Biopharm Posts Nearly 335 Million Yuan Loss in 2023 | MT |
| Mar. 28 | Immunotech Biopharm Ltd Reports Earnings Results for the Full Year Ended December 31, 2023 | CI |
| Sales 2021 | - | Sales 2022 | - | Capitalization | 2.1B 16.48B |
|---|---|---|---|---|---|
| Net income 2021 | -354M -2.77B | Net income 2022 | -318M -2.49B | EV / Sales 2021 | - |
| Net cash position 2021 | 242M 1.9B | Net Debt 2022 | 70.35M 551M | EV / Sales 2022 | - |
| P/E ratio 2021 |
-19.9
x | P/E ratio 2022 |
-6.6
x | Employees | 211 |
| Yield 2021 * |
-
| Yield 2022 |
-
| Free-Float | 44.48% |
More Fundamentals
* Assessed data
More news
More press releases
| 1 day | +5.10% | ||
| 1 week | -3.79% | ||
| Current month | -11.53% | ||
| 1 month | -11.53% | ||
| 3 months | -21.05% | ||
| 6 months | -17.29% | ||
| Current year | -34.00% |
1 week
3.02
3.55
1 month
3.023.75
Current year
3.025.00
1 year
3.025.00
3 years
3.0222.45
5 years
3.0222.45
10 years
3.0222.45
| Managers | Title | Age | Since |
|---|---|---|---|
Yu Wang
CEO | Chief Executive Officer | 57 | 19-08-22 |
Ning Yang
DFI | Director of Finance/CFO | 43 | 19-03-31 |
Yu Zhang
CTO | Chief Tech/Sci/R&D Officer | 60 | 18-12-23 |
| Members of the board | Title | Age | Since |
|---|---|---|---|
Rui Hua Wang
BRD | Director/Board Member | 60 | 23-03-23 |
Ying Dian Wang
BRD | Director/Board Member | 63 | 18-12-31 |
Ran Tao
BRD | Director/Board Member | 59 | 21-08-22 |
| Name | Weight | AuM | 1st Jan change | Investor Rating |
|---|---|---|---|---|
| 0.77% | 4 M€ | -27.92% | ||
| 0.02% | 2 M€ | -.--% |
| Date | Price | Change | Volume |
|---|---|---|---|
| 24-04-24 | 3.3 | +5.10% | 60 000 |
| 24-04-23 | 3.14 | -6.82% | 46,000 |
| 24-04-22 | 3.37 | -2.32% | 0 |
| 24-04-19 | 3.45 | -1.99% | 47,109 |
| 24-04-18 | 3.52 | +0.28% | 31,000 |
Delayed Quote Hong Kong S.E., April 24, 2024 at 04:08 am EDT
More quotes
Immunotech Biopharm Ltd is a China-based investment holding company mainly engaged in the research and development, manufacturing and commercialization of immune cell products for treatments of cancers. Its main products are EAL, CAR-T cell series and TCR-T cell series products. EAL is a multi-target cellular immunotherapy product. It also provides cell cryopreservation services. The Company mainly conducts its businesses in the domestic market.
Calendar
2024-08-19
- Q2 2024 Earnings Release (Projected)
Annual profits - Rate of surprise
| 1st Jan change | Capi. | |
|---|---|---|
| -34.00% | 206M | |
| -1.72% | 105B | |
| +3.73% | 97.5B | |
| +1.92% | 22.19B | |
| -16.16% | 21.33B | |
| -8.49% | 18.68B | |
| -42.33% | 16.6B | |
| -21.38% | 14.52B | |
| +5.65% | 14.09B | |
| +21.96% | 10.99B |
- Stock Market
- Equities
- 6978 Stock
